Publikationen 2017

Publikationen aus dem Jahr 2017

Quidde J, Koch B, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A: Versorgung von Patienten nach Krebserkrankung im Kindes-, Jugend- oder jungen Erwachsenenalter. Journal Onkologie. 2017;(10/2017):862-866

Quidde J, Koch B, Salchow J, Jensen W, von Grundherr J, Escherich G, Rutkowski S, Schulz-Kindermann F, Bergelt C, Bokemeyer C, Sokalska-Duhme M, Bielak S, Calaminus G, Classen C, Rössig C, Faber J, Faller H, Hilgendorf I, Langer T, Metzler M, Schuster S, Niemeyer C, Pierce A, Reinhardt D, Dirksen U, Sander A, Köhler M, Stein A: Das CARE-for-CAYA-Programm. Präventionskonzept für junge Menschen nach Krebserkrankung. Forum. Das offizielle Magazin der Deutschen Krebsgesellschaft e.V.. 2017;(06/2017)

Stellamanns J, Ruetters D, Dahal K, Schillmoeller Z, Huebner J: Visualizing risks in cancer communication: A systematic review of computer-supported visual aids. Patient Educ Couns. 2017 Aug;100(8):1421-1431. doi: 10.1016/j.pec.2017.02.003. Epub 2017 Feb 6. PMID: 28215828

Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD: Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017 Sep 1;3(9):1237-1244. PMID:28448662

van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N; CLL subcommittee; Chronic Malignancies Working Party of the EBMT: Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2017 Dec 18. doi: 10.1038/s41409-017-0023-2. [Epub ahead of print] PMID:29255169

Schmalenberg H, Al-Batran SE, Pauligk C, Zander T, Reichart A, Lindig U, Kleiß M, Müller L, Bolling C, Seufferlein T, Reichardt P, Kullmann F, Eschenburg H, Schmittel A, Egger M, Block A, Goetze TO: CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach. J Cancer Res Clin Oncol. 2017 Dec 28. doi: 10.1007/s00432-017-2565-5. [Epub ahead of print] PMID: 29285668

Huebner J, Prott FJ, Muecke R, Buentzel J, Muenstedt K Dennert, G Micke O: Economic evaluation of complementary and alternative medicine in oncology – is there a difference to conventional medicine? Med Princ Pract. 2017;26(1):41-49. doi: 10.1159/000450645. Epub 2016 Sep 7. PMID: 27607437

Loquai C, Dechent D, Garzarolli M, Kaatz M, Kähler K, Kurschat P, Meiss F, Micke O, Muecke R, Muenstedt K, Nashan D, Stein A, Stoll C, Schmidtmann I, Huebner J: Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma; Med Oncol. 2016 May;33(5):52. doi: 10.1007/s12032-016-0764-6. Epub 2016 Apr 18. PMID: 27090799

Loquai C, Dechent D, Garzarolli M, Kaatz M, Kaehler K, Kurschat P, Meiss F, Micke O, Muecke R, Muenstedt K, Stein A, Nashan D, Stoll C, Schmidtmann I, Huebner J. Use of complementary and alternative medicine: a multicenter cross-sectional study in 1089 melanoma patients. Eur J Cancer. 2017 Jan;71:70-79. doi: 10.1016/j.ejca.2016.10.029. Epub 2016 Dec 14. PMID: 27984769

Erickson N, Boscheri A, Linke B, Huebner J. Systematic review: isocaloric ketogenic dietary regimes for cancer patients; Med Oncol. 2017 May;34(5):72. doi: 10.1007/s12032-017-0930-5. Epub 2017 Mar 28. PMID: 28353094

Ebel MD, Stellamanns J, Keinki C, Rudolph I, Huebner J: Cancer patients and the internet: a survey among German cancer patients; J Cancer Educ. 2017 Sep;32(3):503-508. doi: 10.1007/s13187-015-0945-6. PMID: 26553327

Boehme C, Baron von Osthoff MB, Frey K, Huebner J: Development of a Rating Tool for Mobile Cancer Apps: Information Analysis and Formal and Content-Related Evaluation of Selected Cancer Apps; Canc Educ; J Cancer Educ. 2017 Aug 17. doi: 10.1007/s13187-017-1273-9. [Epub ahead of print] PMID:28819928

Ruetters D, Marten D, Linke B, Keinki C, Muenstedt K, Buentzel J, Micke O, Zell J, Beer AM, Huebner J: Phytotherapy as part of complementary and alternative therapies in cancer care - a protocol for a systematic review; Trace Elements Electrolytes 2017; 34(3):118-123

Erickson N, Buchholz D, Hübner J für die Arbeitsgemeinschaft Prävention und Integrative Onkologie (PRIO) der Deutschen Krebsgesellschaft (DKG). Stellungnahme zu ketogenen und kohlenhydratarmen Diäten bei Menschen mit Krebs. Ernährungs Umschau 2017;64(9): M541–M516. DOI: 10.4455/eu.2017.036

Buentzel J, Kusterer I, Rudolph I, Kubin T, Micke O, Huebner J: Cancer Patients’ Knowledge and Acceptance of Physical Activities for Rehabilitation; In Vivo. 2017 Nov-Dec;31(6):1187-1192. DOI:10.21873/invivo.11188. PMID:29102944

Anlauf M, Aust N, Bertelsen HW, Boscheinen J, Ernst E, Friedrich DR, Grams N, Hoyningen-Huene P, Hübner J, Hucklenbroich P, Raspe H, Reichardt JO, Schmacke N, Schöne-Seifert B, Scholz OR, Taupitz J, Weymayr C.: Münsteraner Memorandum Heilpraktiker. Die Thesen des „Münsteraner Kreises“ zu einer Neuregelung des Heilpraktikerwesens; Ethik Med 2017; doi.org/10.1007/s00481-017-0461-9

Hoeh JC, Schmidt T, Huebner J: Physical activity among cancer survivors - What is their perception and experience? Supp Care Cancer<brhttps://doi.org/10.1007/s00520-017-3977-0

Huebner J, Prott FJ, Muecke R, Stoll C, Buentzel J, Muenstedt K, Micke O: Prevention and Integrative Oncology of the German Cancer Society Working Group. Economic Evaluation of Complementary and Alternative Medicine in Oncology: Is There a Difference Compared to Conventional Medicine? Med Princ Pract. 2017;26(1):41-49. doi: 10.1159/000450645. PMID: 27607437

Steube A, Schenk T, Tretyakov A, Saluz HP: High-intensity UV laser ChIP-seq for the study of protein-DNA interactions in living cells. Nat Commun. 2017 Nov 3;8(1):1303. doi: 10.1038/s41467-017-01251-7. PMID: 29101361

Fleischmann T, Hilgendorf I, Franiel T.: Das Myelosarkom der Hypophyse – eine Rarität eines isolierten Rezidivs einer akuten myeloischen Leukämie. Rofo. 2017 Nov 20. doi: 10.1055/s-0043-122080. [Epub ahead of print]. PMID: 29156477

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V: Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31114. [Epub ahead of print]PMID: 29047142

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N1, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH: Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2017 Nov 1:JCO2017747162. doi: 10.1200/JCO.2017.74.7162. [Epub ahead of print] PMID:29091516
Erickson, D. Buchholz, J.Hübner: Aktualisierte Stellungnahme ketogene und kohlenhydratarme Diäten veröffentlicht. FORUM 5 2017 32:429–430. https://doi.org/10.1007/s12312-017-0332-9

Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG): Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17. PMID: 29054815

Tian Q, Gromov P, Clement JH, Wang Y1, Riemann M, Weih F, Sun XX, Dai MS, Fedorov LM: RHEB1 insufficiency in aged male mice is associated with stress-induced seizures. Geroscience. 2017 Sep 10. doi: 10.1007/s11357-017-9997-3. [Epub ahead of print] PMID: 28891034

Walther G, Stasch S, Kaerger K, Hamprecht A, Roth M, Cornely OA, Geerling G, Mackenzie CR, Kurzai O, von Lilienfeld-Toal M: Fusarium Keratitis in Germany. J Clin Microbiol. 2017 Oct;55(10):2983-2995. doi: 10.1128/JCM.00649-17. Epub 2017 Jul 26. PMID: 28747368

Beck J, Schwarzer A, Gläser D, Mügge LO, Uhlig J, Heyn S, Kragl B, Mohren M, Hoffmann FA, Lange T, Schliwa T, Zehrfeld T, Becker C, Kreibich U, Winkelmann C, Edelmann T, Andrea M, Bill M, Jentzsch M, Schwind S, Niederwieser D, Pönisch W: Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). J Cancer Res Clin Oncol. 2017 Dec;143(12):2545-2553. doi: 10.1007/s00432-017-2504-5. Epub 2017 Aug 21. PMID: 28828689

Metzelder SK, Schroeder T, Lübbert M, Ditschkowski M, Götze K, Scholl S, Meyer RG, Dreger P, Basara N, Fey MF, Salih HR, Finck A3, Pabst T, Giagounidis A, Kobbe G, Wollmer E, Finke J, Neubauer A1, Burchert A: Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer. 2017 Nov;86:233-239. doi: 10.1016/j.ejca.2017.09.016. Epub 2017 Oct 18. PMID: 29055209

Winkelmann N, Schäfer V, Rinke J, Kaiser A, Ernst P, Scholl S, Hochhaus A, Ernst T: Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies. J Cancer Res Clin Oncol. 2017 Sep 14. doi: 10.1007/s00432-017-2518-z. [Epub ahead of print] PMID:28551768

Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B2, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B: Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells. Nat Commun. 2017 Aug 21;8(1):311. doi: 10.1038/s41467-017-00169-4. PMID: 28827518

Inhestern J, Schmalenberg H, Dietz A, Rotter N, Maschmeyer G, Jungehülsing M, Grosse-Thie C, Kuhnt T, Görner M, Sudhoff H, Wittekindt C, Guntinas-Lichius O: A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1). Ann Oncol. 2017 Aug 1;28(8):1917-1922. doi: 10.1093/annonc/mdx202. PMID: 28498880

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A: Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31. PMID: 28364360

Halwas N, Griebel L, Huebner J: eHealth literacy, Internet and eHealth service usage: a survey among cancer patients and their relatives. J Cancer Res Clin Oncol. 2017 Jul 11. doi: 10.1007/s00432-017-2475-6. [Epub ahead of print] PMID: 28699035

Hübner J: Was uns die Methadon-Saga lehrt. FOCUS 37/2017

Allenstein U, Wisotzki EI, Gräfe C, Clement JH, Liu Y, Schroers J, Mayr SG: Binary Fe-Pd submicron structures fabricated through glancing angle deposition (GLAD) for bioapplications. Materials and Design 131 (2017) 366–374. https://doi.org/10.1016/j.matdes.2017.06.032

Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC: Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma. Leukemia. 2017 Aug;31(8):1816-1819. doi: 10.1038/leu.2017.124. Epub 2017 Apr 25. PMID:28439106

Mothes H, Bauschke A, Schuele S, Eigendorff E, Altendorf-Hofmann A, Settmacher: Surgery for colorectal cancer in elderly patients: how can we improve outcome? J Cancer Res Clin Oncol (2017) 143:1879–1889. DOI 10.1007/s00432-017-2438-y. PMID: 28534171

Hübner J, Hartmann M, Wedding U, Gießler W, Schuler U, Hochhaus A: „Strohhalmfunktion“ ohne Evidenz. Deutsches Ärzteblatt | Jg. 114, Heft 33–3, 21. August 2017

R Hehlmann, M Lauseker, S Sau_ele, M Pfirrmann, S Krause, H J Kolb, A Neubauer, D K Hossfeld, C Nerl, A Gratwohl, G M Baerlocher, D Heim, T H Brümmendorf, A Fabarius, C Haferlach, B Schlegelberger, M C Müller, S Jeromin, U Proetel, K Kohlbrenner, A Voskanyan, S Rinaldetti, W Seifarth, B Spieß, L Balleisen, M C Goebeler, M Hänel, A Ho, J Dengler, C Falge, L Kanz, S Kremers, A Burchert, M Kneba, F Stegelmann, C A Köhne, H W Lindemann, C F Waller,MPfreundschuh, K Spiekermann,WE Berdel, LMüller, M Edinger, J Mayer, D W Beelen, M Bentz, H Link, B Hertenstein, R Fuchs, M Wernli, F Schlegel, R Schlag, M de Wit, L Trümper, H Hebart, M Hahn, J Thomalla, C Scheid, P Schafhausen, W Verbeek, M J Eckart, W Gassmann, A Pezzutto, M Schenk, P Brossart, T Geer, S Bildat, E Schäfer, A Hochhaus, J Hasford, for the SAKK and the German CML Study Group, Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants, Leukemia accepted article preview 14 August 2017; doi: 10.1038/leu.2017.253 PMID: 28804124

von Lilienfeld-Toal M: Antiinfektiöse Therapieprinzipien bei akuten Leukämien. Onkologe 2017 · 23:537–542; DOI 10.1007/s00761-017-0223-9; Online publiziert: 12. April 2017 © Springer Medizin Verlag GmbH 2017

Hochhaus A, Höffken K: Citius – altius – fortius. Fortschritte bei neuen Substanzen und Wirkprinzipien in der Onkologie. Onkologe 2017 · 23:586–587. DOI 10.1007/s00761-017-0254-2; © Springer Medizin Verlag GmbH 2017

Sopper S, Mustjoki S, Gjertsen BT, Giles F, Hochhaus A, Janssen JJWM, Porkka K, Wolf D: NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.235. [Epub ahead of print]PMID:28744011

Pulewka K, Wolff D, Herzberg PY, Greinix H, Heussner P, Mumm FHA, von Harsdorf S, Rieger K, Hemmati P, Hochhaus A, Hilgendorf I: Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial. J Cancer Res Clin Oncol. 2017 Aug;143(8):1613-1619. doi: 10.1007/s00432-017-2424-4. Epub 2017 Apr 19.PMID:28424902

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G: Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol.2017 Sep;96(9):1463-1470. doi: 10.1007/s00277-017-3067-x. Epub 2017 Jul 19.PMID:28725989

Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol (2017) 143:2059–2066 DOI 10.1007/s00432-017-2445-z PMID: 28551768

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, J. Richter & C. Buske, on behalf of the ESMO Guidelines Committee: Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 28 (Supplement 4): iv41–iv51, 2017, doi:10.1093/annonc/mdx219

Erickson N, Boscheri A, Linke B, Huebner J. Systematic review: isocaloric ketogenic dietary regimes for cancer patients; Med Oncol 2017; 34:72.PMID:28353094

Goepfert M, Liebl P, Herth N, Ciarlo G, Buentzel J, Huebner J. Aroma oil therapy in palliative care: a pilot study with physiological parameters in conscious as well as unconscious patients; J Cancer Res Clin Oncol; 2017 DOI 10.1007/s00432-017-2460-0, PMID:28634728

Hochhaus A, Mahon FX, le Coutre P, Petrov L, Janssen JJWM, Cross NCP, et al.: Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCRABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of Cancer Research and Clinical Oncology ISSN 0171-5216 Volume 143 Number 7 J Cancer Res Clin Oncol (2017) 143:1225-1233 DOI 10.1007/s00432-017-2359-9, PMID 28224300

Rinke J, Müller JP, Blaess MF, Chase A, Meggendorfer M, Schäfer V, Winkelmann N, Haferlach C, Cross NCP, Hochhaus A, Ernst T: Molecular characterization of EZH2-mutant patients with myelodysplastic/myeloproliferative neoplasms. Leukemia. 2017 Jun 19. doi: 10.1038/leu.2017.190. [Epub ahead of print] PMID:28626218

Rachow T, Schlüter V, Bremer-Streck S, Lindig U, Scholl S, Schlattmann P, Kiehntopf M, Hochhaus A3, von Lilienfeld-Toal M.: Measurement of piperacillin plasma concentrations in cancer patients with suspected infection. Infection. 2017 May 17. doi: 10.1007/s15010-017-1026-z. [Epub ahead of print]PMID:28516432

Stein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, Vinko Tosevski, Krzysztof Warzocha, Claudia Dumrese, Augustin Ferrant, Tobias Gedde-Dahl, Andrzej Hellmann, JeroenJanssen, Boris Labar, Alois Lang, Waleed Majeed, Georgi Mihaylov, Jesper Stentoft, Leif Stenke, Josef Thaler, Noortje Thielen, Gregor Verhoef, Jaroslava Voglova, GertOssenkoppele, Andreas Hochhaus, Henrik Hjorth-Hansen, Satu Mustjoki, Sieghart Sopper, Francis Giles, Kimmo Porkka, Dominik Wolf, Bjørn Tore Gjertsen: Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukaemia treated with nilotinib. Haematologica. 2017 May 18. pii: haematol.2017.167080. doi: 10.3324/haematol.2017.167080. [Epub ahead of print] PMID: 28522574

Bahlis NJ, Corso A, Mugge LO, Shen ZX, Desjardins P, Stoppa AM, Decaux O, de Revel T, Granell M, Marit G, Nahi H, Demuynck H, Huang SY, Basu S, Guthrie TH, Ervin-Haynes A, Marek J, Chen G, Facon T: Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia. 2017 Apr 28. doi: 10.1038/leu.2017.111. [Epub ahead of print]PMID:28373701

Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH: Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. Cancer Res Clin Oncol. 2017 May;143(5):807-820. doi: 10.1007/s00432-017-2354-1. Epub 2017 Feb 23. PMID: 28233092

Gieseler-Halbach S, Meltendorf S, Pierau M, Weinert S, Heidel FH, Fischer T, Handschuh J, Braun-Dullaeus RC, Schrappe M, Lindquist JA, Mertens PR, Thomas U, Brunner-Weinzierl MC: RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts. Cell Death Differ. 2017 Feb;24(2):371-383. doi: 10.1038/cdd.2016.141. Epub 2016 Dec 23. Cell Death Differ. 2017 Feb;24(2):371-383. doi: 10.1038/cdd.2016.141. Epub 2016 Dec 23. PMID: 28009354

Reichenbach F, Wiedenmann C, Schalk E, Becker D, Funk K, Scholz-Kreisel P, Todt F, Wolleschak D, Dohner K, Marquardt JU, Heidel F, Edlich F: Mitochondrial BAX determines the predisposition to apoptosis in human AML.Clin Cancer Res. 2017 Apr 18. pii: clincanres.1941.2016. doi: 10.1158/1078-0432.CCR-16-1941. [Epub ahead of print] PMID: 28420723

Axel R. Göhring, Stefanie Reuter, Joachim H. Clement, Xinlai Cheng, Jannick Theobald, Stefan Wölfl, Ralf Mrowka: Human microRNA-299-3p decreases invasive behavior of cancer cells by downregulation of Oct4 expression and causes apoptosis. PLoS One. 2017 Apr 20;12(4):e0174912. doi: 10.1371/journal.pone.0174912. eCollection 2017. PMID: 28426762

Pulewka K, Wolff D, Herzberg PY, Greinix H, Heussner P, Mumm FHA, von Harsdorf S, Rieger K, Hemmati P, Hochhaus A, Hilgendorf I: Physical and psychosocial aspects of adolescent and young adults after allogeneic hematopoietic stem-cell transplantation: results from a prospective multicenter trial. J Cancer Res Clin Oncol. 2017 Apr 19. doi: 10.1007/s00432-017-2424-4. [Epub ahead of print] PMID:28424902

Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE: Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 Apr 7. doi: 10.1002/cncr.30558. [Epub ahead of print]. PMID: 28387926

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G: Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017 Mar 17. doi: 10.1038/leu.2017.63. [Epub ahead of print] PMID:28218239

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ: Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.PMID:28273028

Chan LN, Chen Z, Braas D, Lee JW, Xiao G, Geng H, Cosgun KN, Hurtz C, Shojaee S, Cazzaniga V, Schjerven H, Ernst T, Hochhaus A, Kornblau SM, Konopleva M, Pufall MA, Cazzaniga G, Liu GJ9, Milne TA, Koeffler HP,12, Ross TS, Sánchez-García I, Borkhardt A, Yamamoto KR, Dickins RA, Graeber TG, Müschen M: Metabolic gatekeeper function of B-lymphoid transcription factors. Nature. 2017 Feb 23;542(7642):479-483. doi: 10.1038/nature21076. Epub 2017 Feb 13. PMID:28192788

Andreas Hochhaus, Franҫois‑Xavier Mahon, Philipp le Coutre, Ljubomir Petrov, Jeroen J. W. M. Janssen, Nicholas C. P. Cross, Delphine Rea, Fausto Castagnetti, Andrzej Hellmann, Gianantonio Rosti, Norbert Gattermann, Maria Liz Paciello Coronel, Maria Asuncion Echeveste Gutierrez, Valentin Garcia‑Gutierrez, Beatrice Vincenzi, Luca Dezzani, Francis J. Giles: Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. J Cancer Res Clin Oncol DOI 10.1007/s00432-017-2359-9. Received: 25 January 2017 / Accepted: 27 January 2017 © The Author(s) 2017. This article is published with open access at Springerlink.com

Billing M, Gräfe C, Saal A, Biehl, Clement JH, Dutz S, Weidner S, Schacher FH: Zwitterionic Iron Oxide (γ-Fe2 O3 ) Nanoparticles Based on P(2VP-grad-AA) Copolymers. Macromol Rapid Commun. 2017 Feb;38(4). doi: 10.1002/marc.201600637. Epub 2016 Dec 22. PMID:28004458

Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C: Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12. PMID:27941792

Gupta N, Edelmann B, Schnoeder TM, Saalfeld FC, Wolleschak D, Kliche S, Schraven B, Heidel FH* and Fischer T* JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1 (VCAM1)-coated surface. Leukemia 2017, in press. *equal contribution, shared corresponding authors. Leukemia. 2017 Jan 18. doi: 10.1038/leu.2017.26. [Epub ahead of print]. PMID:28096537

Nishanth G, Wolleschak D, FahldieckC, Fischer T, Mullally A, Perner F, Schnöder TM, Heidel FH*, Schlüter D*. *equal contribution, shared corresponding authors. Gain of function in Jak2V617F positive T-cells. Leukemia. 2017 Jan 11. doi: 10.1038/leu.2017.6. [Epub ahead of print]PMID:28074070

Maximilian Fleischmann, Ulf Schnetzke, Karin G. Schrenk, Volker Schmidt, Herbert G. Sayer, Inken Hilgendorf, Andreas Hochhaus, Sebastian Scholl: Outcome of FLT3‑ITD‑positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24. PMID:27778197

Annamaria Brioli &, Lars-Olof Mügge, Andreas Hochhaus & Marie von Lilienfeld-Toal: Safety issues and managment of toxicities associated with new treatments for multiple myeloma. Expert Review of Hematology. Received 31 Oct 2016, Accepted 17 Jan 2017, Accepted author version posted online: 24 Jan 2017. http://dx.doi.org/10.1080/17474086.2017.1284584

Hilgendorf I, Greinix H, Halter J, Lawitschka A, Wolff D: Vaccination of allogeneic hematopoietic stem cell transplant recipients-what should be considered? Ann Hematol. 2017 Jan 17. doi: 10.1007/s00277-017-2922-0. [Epub ahead of print] PMID: 28097373

Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M: No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. J Cancer Res Clin Oncol. 2017 Jan 12. doi: 10.1007/s00432-016-2321-2. [Epub ahead of print] PMID:28083711

Schütz C, Inselmann S, Sausslele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A: Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia (2017) 31, 829–836; doi:10.1038/leu.2017.9; published online 27 January 2017 PMID: 28074067

Sieghart Sopper, Satu Mustjoki, Deborah White, Timothy Hughes, Peter Valent, Andreas Burchert, Bjørn T. Gjertsen, G¨unther Gastl, Matthias Baldauf, Zlatko Trajanoski, Frank Giles, Andreas Hochhaus, Thomas Ernst, Thomas Schenk, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Kimmo Porkka, and Dominik Wolf: Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. J Clin Oncol 35:175-184. 2017 Jan 10;35(2):175-184. Epub 2016 Nov 7. PMID: 28056193

A. Hochhaus: Chronische myeloproliferative Neoplasien. Onko Update 2017 – Handbuch ONKOLOGIE 2017

Hübner J: Was uns die Methadon-Saga lehrt. FOCUS 37/2017

Hochhaus A: Chronische myeloproliferative Neoplasien, Onko Update 2017 – Handbuch ONKOLOGIE 2017

Brioli A, Mügge LO, Hochhaus A, von Lilienfeld-Toal M: Safety issues and managment of toxicities associated with new treatments for multiple myeloma. Journal Expert Review of Hematology Volume 10, 2017 - Issue 3, Pages 193-205 | Received 31 Oct 2016, Accepted 17 Jan 2017, Accepted author version posted online: 24 Jan 2017, Published online: 27 Jan 2017 http://dx.doi.org/10.1080/17474086.2017.1284584

Hochhaus A: Ein Wirkstoff für mehrere Krebserkrankungen. Perspektiven der Onkologie 1/2017 | Deutsches Ärzteblatt

Fischer M, Müller JP, Spies-Weisshart B, Gräfe C, Kurzai O, Hünniger K, Hochhaus A , Sebastian Scholl S, Schnetzke U: Isoform Localization of Dectin-1 Regulates the Signaling Quality of Anti-Fungal Immunity. Eur J Immunol . 2017 May;47(5):848-859. doi: 10.1002/eji.201646849. Epub 2017 Apr 13. PMID: 28303575